News
Maven Clinic acquires digital health company Naytal to accelerate UK expansion
The UK is Maven’s largest market outside of the US, with more than 70 employer clients
Maven Clinic has acquired the London-based digital health company Naytal to accelerate its growth in the UK and Europe.
The virtual clinic, which partners with employers to reduce costs of care and improve clinical outcomes, has more than 70 employer UK clients with employees in the region.
The acquisition of Naytal is hoped to enhance its ability to serve its members in the UK and provide families with access to personalised care.
“Maven’s digital platform has been built to address gaps in reproductive and maternal health globally and meet each member, no matter where they are in the world, with the same level of high-quality, personalised care,” said Kate Ryder, founder and CEO of Maven Clinic.
“With our acquisition of Naytal, our rapidly expanding UK and European membership will have even greater access to timely support that meets their unique needs through a partner deeply embedded in the region.”
Leila Thabet, founder and CEO of Naytal, said: “Women’s health is universally misunderstood and women and families around the world are too often let down by the healthcare systems designed to support them.
“Maven has set the standard and paved the way for innovation for women’s and family healthcare globally and was an inspiration for me when I started Naytal.
“I am thrilled to be joining Kate and the team on their mission to provide better access to quality healthcare for women and families in the UK and throughout Europe.”
Founded in 2021 by entrepreneur Leila Thabet, Naytal provides on-demand access to women’s and family health experts to support a range of reproductive healthcare needs, including fertility and pregnancy care as well as menopause.
Thabet, the company’s founder and CEO, will join Maven as regional vice president, global growth and partnerships, and many of Naytal’s UK-based women’s health providers will join Maven’s network of providers around the world.
In November, Maven raised US$90m in funding to invest in personalisation across its reproductive health platform, bringing its total funding to US$300m.
The platform allows its members to access local support through care advocates who understand the cultural and regulatory context of each region, specialists aligned to member needs, culture, language and time zone, and local steerage to in-person care.
Cancer
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now






